Credit: Shutterstock

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

Any­one ex­pect­ing much up­beat news for biotech in Q1 of this year was in for a sore dis­ap­point­ment.

Our num­bers czar, Deal­For­ma’s Chris Doko­ma­ji­lar, crunched the stats for the first 3 months of the year and found plen­ty of down­drafts all around, with just a cou­ple of sil­ver lin­ings to look at.

Biotech IPOs, as you might ex­pect in a sav­age bear mar­ket, have large­ly evap­o­rat­ed from the scene — though some have made the leap with some ear­ly plan­ning. SPACs, briefly the belle of the Wall Street ball, flared with fast cash and burned out, as you can see in the chart be­low.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.